Vitamin K2 (150 mcg) - 30 ct Vcp

The "Calcium Paradox": How Vitamin K2 Protects Your Heart & Bones

In nutritional medicine, the "Calcium Paradox" describes a dangerous biological mistake: what happens when calcium leaves the bones weak (leading to osteoporosis) while building up inside the arteries (causing arterial stiffness and plaque).

Your body relies on two key proteins to move calcium correctly. Both proteins are born "asleep" and require Vitamin K2 (as MK-7) to activate them:

1. Osteocalcin (The Bone Magnet): Made by your bone-building cells, this protein remains inactive until Vitamin K2 turns it on. Once activated, osteocalcin binds tightly to circulating calcium, pulling it directly into the bone matrix to maintain mineral density and skeletal resilience.
2. Matrix Gla Protein / MGP (The Arterial Shield): MGP is the only known natural defense mechanism your blood vessels have against hardening. Active Vitamin K2 switches MGP on, allowing it to sweep excess calcium out of arterial walls and soft tissues, keeping blood pathways supple and elastic.

Without adequate Vitamin K2, calcium is left floating unsupervised in your bloodstream—raising the risk of calcification where you least want it.

Why Fermented Chickpea MK-7 Outperforms Other Forms

Not all Vitamin K is identical. While grocery items like spinach contain Vitamin K1 (Phylloquinone), K1 is primarily used by the liver for normal blood clotting and leaves your system in just 2 to 3 hours. Synthetic MK-4 also clears out in hours, requiring high doses taken multiple times daily.

Because MK-7 stays active in your bloodstream for nearly three full days, a single 150 mcg dose creates a steady, 24-hour protective shield for your cardiovascular system and bones.

Scientifically Validated Health Benefits

Unlike trendy wellness fads, the benefits of Vitamin K2 (Menaquinone-7) are backed by multi-year, randomized, double-blind human clinical trials:

• Prevents Age-Related Bone Mineral Loss: A 3-year randomized clinical trial published in Osteoporosis International followed 244 healthy postmenopausal women and proved that low-dose daily MK-7 significantly slowed the age-related decline in bone mineral density (BMD) and bone strength at both the lumbar spine and femoral neck.
• Improves Arterial Elasticity & Reduces Stiffness: In another landmark 3-year study published in Thrombosis and Haemostasis, daily MK-7 supplementation significantly decreased arterial stiffness in women, visibly improving vascular elasticity as measured by pulse wave velocity.
• Reduces Coronary Heart Risks: The famous population-based Rotterdam Study (4,807 subjects followed over 7–10 years) confirmed that individuals with the highest intake of dietary menaquinone (K2) had a 57% lower rate of coronary heart disease mortality and substantially lower aortic calcification.
• The Ideal Partner for Vitamin D3: When paired with Vitamin D3, Vitamin K2 prevents the hypercalcemia-like tissue stress that can occur when high amounts of calcium enter the body without proper biochemical navigation.

Peer-Reviewed Scientific Citations (Double-Checked PMIDs):

• Knapen MH, et al. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int. 2013;24(9):2499-507. PMID: 23525894.
• Knapen MH, et al. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial. Thromb Haemost. 2015;113(5):1135-44. PMID: 25694037.
• Geleijnse JM, et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr. 2004;134(11):3100-5. PMID: 15514282.
• Schurgers LJ, et al. Vitamin K-containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7. Blood. 2007;109(8):3279-83. PMID: 17158229.
• Gast GC, et al. A high menaquinone intake reduces the incidence of coronary heart disease. Nutr Metab Cardiovasc Dis. 2009;19(7):504-10. PMID: 19179058.